ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)

also known as antithymocyte globulin · ATG · Thymoglobulin · horse-antithymocyte globulin · Anti-thymocyte globulin (ATG) · hATG · ATGAM · Equine anti-thymocyte globulin · +24 more

Protein / enzyme biologic

Developed for: myelodysplastic syndrome · leukemia · aplastic anemia · graft versus host disease · myelodysplastic/myeloproliferative disease · myeloproliferative neoplasm · plasma cell neoplasm · type 1 diabetes mellitus
+57 more
· disease related to hematopoietic stem cell transplant · Fanconi anemia · plasma cell myeloma · acute leukemia · Hodgkins lymphoma · lymphoma · severe congenital neutropenia · Diamond-Blackfan anemia · kidney cancer · myelofibrosis · acquired aplastic anemia · atypical chronic myeloid leukemia, BCR-ABL1 negative · breast cancer · cancer · Chediak-Higashi syndrome · childhood malignant neoplasm · chronic myelomonocytic leukemia · congenital amegakaryocytic thrombocytopenia · hematopoietic and lymphoid cell neoplasm · immunodeficiency disease · juvenile myelomonocytic leukemia · multiple sclerosis · neuroblastoma · non-Hodgkin lymphoma · Shwachman-Diamond syndrome · sickle cell disease · systemic sclerosis · thalassemia · X-linked lymphoproliferative syndrome · acute graft versus host disease · acute liver failure · acute myeloid leukemia · anemia · B-cell chronic lymphocytic leukemia · benign neoplasm · central nervous system vasculitis · cerebellar degeneration · chronic inflammatory demyelinating polyradiculoneuropathy · cytomegalovirus infection · disease arising from reactivation of latent virus · disease related to transplantation · GATA2 deficiency with susceptibility to MDS/AML · Griscelli syndrome · ischemic disease · Lambert-Eaton myasthenic syndrome · Langerhans cell histiocytosis · liver failure · melanoma · myasthenia gravis · neuromyelitis optica · opsoclonus-myoclonus syndrome · Rasmussen subacute encephalitis · refractory plasma cell neoplasm · stiff-person syndrome · systemic lupus erythematosus · hematologic disorder · transplant rejection
Investigated by: National Cancer Institute (NCI) · Fred Hutchinson Cancer Center · Masonic Cancer Center, University of Minnesota · National Heart, Lung, and Blood Institute (NHLBI) · Nanfang Hospital, Southern Medical University · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
+82 more
· Peking University People's Hospital · University of California, San Francisco · Asan Medical Center · Chinese PLA General Hospital · City of Hope Medical Center · Columbia University · Genzyme, a Sanofi Company · M.D. Anderson Cancer Center · National Institute of Allergy and Infectious Diseases (NIAID) · Roswell Park Cancer Institute · Ann & Robert H Lurie Children's Hospital of Chicago · Barbara Ann Karmanos Cancer Institute · First Affiliated Hospital of Guangxi Medical University · Fujian Medical University · Fujian Medical University Union Hospital · Guangzhou General Hospital of Guangzhou Military Command · Immune Tolerance Network (ITN) · Memorial Sloan Kettering Cancer Center · Sanofi · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · University of Alabama at Birmingham · Alliance for Clinical Trials in Oncology · American Diabetes Association · Amgen · Assiut University · Beijing 302 Hospital · Beth Israel Deaconess Medical Center · Blood and Marrow Transplant Group of Georgia · Camillo Ricordi and Jay Skyler · Central South University Xiangya Hospital · Chinese Academy of Medical Sciences · Diabetes Research Institute Foundation · Eledon Pharmaceuticals · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · European Society for Blood and Marrow Transplantation · Fairview University Medical Center · Guangdong Provincial People's Hospital · Guangzhou First People's Hospital · H. Lee Moffitt Cancer Center and Research Institute · Haukeland University Hospital · ITB-Med LLC · Institut Paoli-Calmettes · Jonsson Comprehensive Cancer Center · Juvenile Diabetes Research Foundation · Mayo Clinic · Milton S. Hershey Medical Center · National Center for Research Resources (NCRR) · National Institutes of Health Clinical Center (CC) · National Marrow Donor Program · Neal Young, M.D. · Northside Hospital, Inc. · Northwestern Memorial Hospital · Office of Rare Diseases (ORD) · Oxford University Hospitals NHS Trust · PETHEMA Foundation · Peking University People's Hospital, Peking University Institute of Hematology · Rare Diseases Clinical Research Network · SWOG Cancer Research Network · Southern Medical University, China · St. Jude Children's Research Hospital · Stanford University · Targazyme, Inc. · Tatsuo Kawai, MD, PhD · The Cleveland Clinic · The First Affiliated Hospital of Zhengzhou University · The Leona M. and Harry B. Helmsley Charitable Trust · Third Affiliated Hospital, Sun Yat-Sen University · Tongji Hospital · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · University Health Network, Toronto · University of California, Los Angeles · University of California, San Diego · University of Colorado, Denver · all 88 on the full record

Trials 109 · started per year

today

199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT06972069	May 2025 → Dec 2030 expected	disease related to solid organ transplantation, kidney failure	Tatsuo Kawai, MD, PhD	Recruiting	No outcome recorded
Phase 19 trials
Phase 1	NCT05757310	Nov 2024 → Jun 2027 expected	aplastic anemia	City of Hope Medical Center	Recruiting	No outcome recorded
Phase 1	NCT04098393	Sep 2019 → Sep 2026 expected	hematopoietic and lymphoid cell neoplasm	Memorial Sloan Kettering Cancer Center	Active not recruiting	No outcome recorded
Phase 1	NCT00972101	Sep 2009 → Sep 2011	disease related to hematopoietic stem cell transplant, leukemia, lymphoma	M.D. Anderson Cancer Center	Withdrawn	No outcome recorded
Phase 1	NCT00697684	Jun 2008 → Dec 2020	B-cell chronic lymphocytic leukemia, Hodgkins lymphoma, acute myeloid leukemia, myelodysplastic syndrome +1	Beth Israel Deaconess Medical Center	Completed	No outcome recorded
Phase 1	NCT00295971	Apr 2005 → Dec 2011	congenital amegakaryocytic thrombocytopenia, leukemia, myelodysplastic syndrome, severe congenital neutropenia	University of California, San Francisco	Completed	No outcome recorded
Phase 1	NCT00301951	Sep 2004 → Jul 2009	leukemia, myelodysplastic syndrome, plasma cell neoplasm	University of California, San Francisco	Completed	No outcome recorded
Phase 1	NCT00436761	May 2004 → ?	childhood malignant neoplasm	Milton S. Hershey Medical Center	Unknown	No outcome recorded
Phase 1	NCT00017641	Apr 2001 → ?	systemic lupus erythematosus	Northwestern Memorial Hospital	Unknown	No outcome recorded
Phase 1	NCT00014755	Dec 1997 → ?	multiple sclerosis	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 1/215 trials
Phase 1/2	NCT07634562	Aug 2026 → Aug 2031 expected	liver failure	Stanford University	Not yet recruiting	No outcome recorded
Phase 1/2	NCT02586831	Jun 2024	hypoglycemia, type 1 diabetes mellitus	Camillo Ricordi and Jay Skyler	Withdrawn	No outcome recorded
Phase 1/2	NCT01983761	Nov 2013 → Mar 2014	Hodgkins lymphoma, disease related to transplantation, leukemia, myelodysplastic syndrome +1	Targazyme, Inc.	Unknown	No outcome recorded
Phase 1/2	NCT01509300	Jan 2012 → Dec 2013	acute leukemia, cancer, myelodysplastic syndrome	Asan Medical Center	Unknown	No outcome recorded
Phase 1/2	NCT01033552	Jan 2010 → Aug 2021	epidermolysis bullosa	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 1/2	NCT01105273	Jul 2009 → Jul 2012	aplastic anemia	Asan Medical Center	Completed	No outcome recorded
Phase 1/2	NCT00801931	Sep 2007 → May 2009	anemia, immunodeficiency disease, leukemia, lymphoma +1	Columbia University	Terminated	No outcome recorded
Phase 1/2	NCT00802113	Jun 2003 → Oct 2014	Hodgkins lymphoma, non-Hodgkin lymphoma	Columbia University	Completed	No outcome recorded
Phase 1/2	NCT00054340	Oct 2002 → Sep 2006	graft versus host disease, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease +1	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT00305708	Aug 2000 → Jul 2004	Diamond-Blackfan anemia, Fanconi anemia, congenital amegakaryocytic thrombocytopenia, leukemia +1	University of California, San Francisco	Completed	No outcome recorded
Phase 1/2	NCT00365287	Jun 2000 → Dec 2005	breast cancer, kidney cancer, leukemia, myelodysplastic syndrome +1	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 1/2	NCT00630253	Feb 2000 → Oct 2020	Fanconi anemia	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 1/2	NCT00005898	Feb 2000 → ?	Fanconi anemia	University of Minnesota	Completed	No outcome recorded
Phase 1/2	NCT00167219	Nov 1999 → Jul 2022	juvenile myelomonocytic leukemia	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 1/2	NCT00003552	Jan 1999 → Oct 2002	melanoma	National Heart, Lung, and Blood Institute (NHLBI)	Terminated	No outcome recorded

Phase 259 trials
Phase 2	NCT07216391	Jul 2026 → Nov 2029 expected	type 1 diabetes mellitus	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Not yet recruiting	No outcome recorded
Phase 2	NCT06455319	Nov 2025 → Nov 2028 expected	type 1 diabetes mellitus	University of Florida	Recruiting	No outcome recorded
Phase 2	NCT06315309	Apr 2025 → Dec 2026 expected	acute graft versus host disease, acute leukemia, myelodysplastic syndrome, myeloproliferative neoplasm	University of Alabama at Birmingham	Recruiting	No outcome recorded
Phase 2	NCT06265584	Apr 2025 → Aug 2028 expected	acute leukemia, myelodysplastic syndrome, myeloproliferative neoplasm	University of Alabama at Birmingham	Recruiting	No outcome recorded
Phase 2	NCT06238245	Feb 2024 → Dec 2025	graft versus host disease, hematopoietic and lymphoid cell neoplasm	Beijing 302 Hospital	Unknown	No outcome recorded
Phase 2	NCT04291703	Nov 2023 → Dec 2024	type 1 diabetes mellitus	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Terminated	No outcome recorded
Phase 2	NCT05579769	Mar 2023 → May 2024	myeloid neoplasm	St. Jude Children's Research Hospital	Terminated	No outcome recorded
Phase 2	NCT05303727	Aug 2022 → Aug 2027 expected	neuroblastoma	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Not yet recruiting	No outcome recorded
Phase 2	NCT04862221	Feb 2022 → Aug 2026 overdue	acute liver failure, hepatic encephalopathy, immune dysregulation, autoimmunity, and autoinflammation	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Recruiting	No outcome recorded
Phase 2	NCT05132166	Dec 2021 → Apr 2026 overdue	graft versus host disease	University Health Network, Toronto	Active not recruiting	No outcome recorded
Phase 2	NCT03602898	Jun 2021 → Sep 2023	Hodgkins lymphoma, acute lymphoblastic leukemia, chronic myeloid leukemia, chronic myelomonocytic leukemia +3	Fred Hutchinson Cancer Center	Withdrawn	No outcome recorded
Phase 2	NCT04761770	Feb 2021 → Feb 2027 expected	atypical chronic myeloid leukemia, BCR-ABL1 negative, chronic myelomonocytic leukemia, myelodysplastic syndrome	Memorial Sloan Kettering Cancer Center	Active not recruiting	No outcome recorded
Phase 2	NCT06572462	Dec 2020 → Dec 2024 overdue	cytomegalovirus infection, disease arising from reactivation of latent virus, disease related to hematopoietic stem cell transplant	Chinese PLA General Hospital	Recruiting	No outcome recorded
Phase 2	NCT04778618	Dec 2020 → Jul 2022	disease related to hematopoietic stem cell transplant	Chinese PLA General Hospital	Unknown	No outcome recorded
Phase 2	NCT04304820	May 2020 → Dec 2024 overdue	aplastic anemia	National Heart, Lung, and Blood Institute (NHLBI)	Recruiting	No outcome recorded
Phase 2	NCT06098326	Mar 2018 → Dec 2026 expected	myelodysplastic syndrome	Asan Medical Center	Active not recruiting	No outcome recorded
Phase 2	NCT03412409	Feb 2018 → Sep 2025	acute leukemia, myelodysplastic syndrome	Peking University People's Hospital	Unknown	No outcome recorded
Phase 2	NCT03412266	Feb 2018 → Mar 2023	myelodysplastic syndrome	Peking University People's Hospital	Unknown	No outcome recorded
Phase 2	NCT03395860	May 2017 → May 2020	graft versus host disease	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Unknown	No outcome recorded
Phase 2	NCT02215200	Dec 2014 → Aug 2017	type 1 diabetes mellitus	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	No outcome recorded
Phase 2	NCT02171104	Jul 2014 → Jan 2026 overdue	Hurler syndrome, Krabbe disease, Niemann-Pick disease type B, Niemann-Pick disease, type C2 +15	Masonic Cancer Center, University of Minnesota	Active not recruiting	No outcome recorded
Phase 2	NCT01909245	Oct 2013 → Sep 2026 expected	type 1 diabetes mellitus	City of Hope Medical Center	Active not recruiting	No outcome recorded
Phase 2	NCT01624805	Jun 2012 → Jun 2029 expected	aplastic anemia, myelodysplastic syndrome	M.D. Anderson Cancer Center	Recruiting	No outcome recorded
Phase 2	NCT01413100	Sep 2011 → Sep 2023	systemic sclerosis	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 2	NCT01116232	Aug 2010 → May 2013	graft versus host disease, leukemia, lymphoproliferative syndrome, myelodysplastic syndrome +2	Barbara Ann Karmanos Cancer Institute	Terminated	No outcome recorded
Phase 2	NCT00944749	Aug 2009 → Dec 2015	aplastic anemia	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 2	NCT00923364	May 2009 → Jun 2014	GATA2 deficiency with susceptibility to MDS/AML, myelodysplastic syndrome	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00716066	Jun 2008 → Dec 2025 overdue	Lambert-Eaton myasthenic syndrome, Rasmussen subacute encephalitis, central nervous system vasculitis, cerebellar degeneration +5	Fred Hutchinson Cancer Center	Active not recruiting	No outcome recorded
Phase 2	NCT00635024	May → Jul 2008	plasma cell myeloma	Mayo Clinic	Terminated	No outcome recorded
Phase 2	NCT00691015	May 2008 → Apr 2014	leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloproliferative neoplasm +1	Barbara Ann Karmanos Cancer Institute	Completed	No outcome recorded
Phase 2	NCT00617929	Jan 2008 → Oct 2014	cancer	Masonic Cancer Center, University of Minnesota	Terminated	No outcome recorded
Phase 2	NCT00613561	Dec 2007 → Dec 2012	immunodeficiency disease	Ann & Robert H Lurie Children's Hospital of Chicago	Unknown	No outcome recorded
Phase 2	NCT00515099	Aug 2007 → Jun 2012	type 1 diabetes mellitus	National Institute of Allergy and Infectious Diseases (NIAID)	Terminated	No outcome recorded
Phase 2	NCT00589563	May 2007 → Feb 2012	graft versus host disease, infectious disease, leukemia, myelodysplastic syndrome +5	City of Hope Medical Center	Completed	No outcome recorded
Phase 2	NCT00787761	Apr 2007 → Jul 2010	kidney cancer, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease +2	Northside Hospital, Inc.	Completed	No outcome recorded
Phase 2	NCT00466843	Apr 2007 → Feb 2010	myelodysplastic syndrome	Office of Rare Diseases (ORD)	Unknown	No outcome recorded
Phase 2	NCT00802568	Apr 2007 → May 2011	plasma cell myeloma	Institut Paoli-Calmettes	Completed	No outcome recorded
Phase 2	NCT00346151	Dec 2006 → Feb 2010	—	National Institute of Allergy and Infectious Diseases (NIAID)	Terminated	No outcome recorded
Phase 2	NCT00346359	Mar 2006 → Nov 2007	graft versus host disease, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease +1	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00719849	Nov 2005 → Nov 2008	leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, plasma cell neoplasm	Fred Hutchinson Cancer Center	Terminated	No outcome recorded
Phase 2	NCT00378768	Nov 2005 → Jun 2007	plasma cell myeloma	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00611351	Jun 2005 → Feb 2008	graft versus host disease, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease +2	University of Nebraska	Completed	No outcome recorded
Phase 2	NCT01231841	Mar 2005 → Dec 2010	aplastic anemia	The Cleveland Clinic	Completed	No outcome recorded
Phase 2	NCT01056614	Sep 2004 → Aug 2005	acute myeloid leukemia with 11q23 abnormalities, acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22), acute myeloid leukemia with t(8;21)(q22;q22) translocation, acute myeloid leukemia, del(5q31-q32) +7	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00217386	Mar 2004 → Dec 2007	leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00074269	Jul 2003 → Mar 2008	breast cancer	University of California, San Diego	Terminated	No outcome recorded
Phase 2	NCT00053196	Dec 2002 → Nov 2006	leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, plasma cell myeloma	Alliance for Clinical Trials in Oncology	Completed	No outcome recorded
Phase 2	NCT00303719	Mar 2002 → May 2019	kidney cancer, leukemia, myelodysplastic syndrome, plasma cell myeloma	Masonic Cancer Center, University of Minnesota	Terminated	No outcome recorded
Phase 2	NCT00016419	Aug 2001 → Jul 2003	leukemia, myelodysplastic syndrome	SWOG Cancer Research Network	Completed	No outcome recorded
Phase 2	NCT00017550	Sep 2000 → Nov 2003	myelodysplastic syndrome	Genzyme, a Sanofi Company	Completed	No outcome recorded
Phase 2	NCT00005937	Jun 2000 → Mar 2008	myelodysplastic syndrome	Neal Young, M.D.	Completed	No outcome recorded
Phase 2	NCT00016458	Jun 2000 → ?	systemic sclerosis	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00001964	Mar 2000 → Dec 2003	acquired aplastic anemia	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 2	NCT00005853	Dec 1999 → Aug 2005	leukemia, myelodysplastic syndrome	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00001839	Dec 1998 → May 2000	myelodysplastic syndrome	National Institutes of Health Clinical Center (CC)	Completed	No outcome recorded
Phase 2	NCT00003913	Dec 1998 → Aug 2005	leukemia, lymphoma, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00001749	Jul 1998 → Jul 2005	Fanconi anemia	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 2	NCT00001626	Jun 1997 → Feb 2001	aplastic anemia	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 2	NCT00005852	Jun 1996 → Jul 2007	graft versus host disease, leukemia, myelodysplastic syndrome, myeloproliferative neoplasm +1	H. Lee Moffitt Cancer Center and Research Institute	Terminated	No outcome recorded

Phase 2/36 trials
Phase 2/3	NCT03295058	Jan → Dec 2019	aplastic anemia	Assiut University	Unknown	No outcome recorded
Phase 2/3	NCT03631563	Mar 2013 → Dec 2018	graft versus host disease	Fujian Medical University	Unknown	No outcome recorded
Phase 2/3	NCT01019876	Sep 2002 → Sep 2021	Fanconi anemia, bone marrow failure syndrome, osteopetrosis, severe combined immunodeficiency	Columbia University	Completed	No outcome recorded
Phase 2/3	NCT00176852	Jun 2002 → Mar 2014	Diamond-Blackfan anemia, Shwachman-Diamond syndrome, severe congenital neutropenia, sickle cell disease +1	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 2/3	NCT00176826	Sep 2000 → Aug 2012	Chediak-Higashi syndrome, Griscelli syndrome, Langerhans cell histiocytosis, X-linked lymphoproliferative syndrome	Masonic Cancer Center, University of Minnesota	Terminated	No outcome recorded
Phase 2/3	NCT00003816	Oct 1998 → Jul 2019	benign neoplasm, childhood malignant neoplasm, leukemia, lymphoma +3	Roswell Park Cancer Institute	Completed	No outcome recorded
Phase 35 trials
Phase 3	NCT05166967	Jan 2022 → Feb 2024	disease related to hematopoietic stem cell transplant	Chinese PLA General Hospital	Completed	No outcome recorded
Phase 3	NCT03477500	Mar 2018 → Nov 2026 expected	multiple sclerosis	Haukeland University Hospital	Active not recruiting	No outcome recorded
Phase 3	NCT01239563	Jan 2011 → May 2012	ischemic disease	University of Oxford	Unknown	No outcome recorded
Phase 3	NCT01163942	Mar 2001 → Jun 2008	aplastic anemia	European Society for Blood and Marrow Transplantation	Terminated	No outcome recorded
Phase 3	NCT00004474	Sep 1998 → Aug 2007	aplastic anemia	Roswell Park Cancer Institute	Completed	No outcome recorded
Phase 45 trials
Phase 4	NCT04203108	Sep 2019 → Aug 2021	—	Nanfang Hospital, Southern Medical University	Unknown	No outcome recorded
Phase 4	NCT03608059	Jul 2018 → Aug 2023	myeloid neoplasm	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Completed	No outcome recorded
Phase 4	NCT01883180	Jun 2013 → Sep 2017	disease related to hematopoietic stem cell transplant, viral infectious disease	Nanfang Hospital, Southern Medical University	Completed	No outcome recorded
Phase 4	NCT01997372	Dec 2010 → Dec 2013	acquired aplastic anemia	Chinese Academy of Medical Sciences	Unknown	No outcome recorded
Phase 4	NCT00488436	May 2002 → Jun 2007	myelodysplastic syndrome	PETHEMA Foundation	Completed	No outcome recorded
Phase not applicable9 trials
—	NCT02487069	Jun 2015 → Jan 2020	acute leukemia, chronic myeloid leukemia, myelodysplastic syndrome	Nanfang Hospital, Southern Medical University	Completed	No outcome recorded
—	NCT02162420	Jan 2015 → Aug 2024	aplastic anemia, dyskeratosis congenita	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
—	NCT02179359	Sep 2014 → Nov 2024	Diamond-Blackfan anemia, Glanzmann thrombasthenia, Shwachman-Diamond syndrome, paroxysmal nocturnal hemoglobinuria +3	Masonic Cancer Center, University of Minnesota	Terminated	No outcome recorded
—	NCT02643589	Jun 2013 → Jun 2016	disease related to hematopoietic stem cell transplant	Nanfang Hospital, Southern Medical University	Unknown	No outcome recorded
—	NCT00856388	Jan 2009 → Aug 2012	Burkitt lymphoma, Fanconi anemia, Hodgkins lymphoma, MALT lymphoma +33	Roswell Park Cancer Institute	Completed	No outcome recorded
—	NCT00093587	Aug 2004 → ?	graft versus host disease, leukemia	Jonsson Comprehensive Cancer Center	Unknown	No outcome recorded
—	NCT00301860	Jan 2003 → Mar 2007	leukemia, lymphoma	University of California, San Francisco	Terminated	No outcome recorded
—	NCT00427336	Dec 2000 → Aug 2009	aplastic anemia	M.D. Anderson Cancer Center	Completed	No outcome recorded
—	NCT00006054	Mar 2000 → Dec 2002	Bruton-type agammaglobulinemia, Chediak-Higashi syndrome, Wiskott-Aldrich syndrome, X-linked lymphoproliferative syndrome +6	Fairview University Medical Center	Terminated	No outcome recorded

Also used as a comparator or background therapy in 177 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 117 trials
Phase 1	NCT04571203 Background	May 2022 → Oct 2027 expected	—	Stanford University	Recruiting	No outcome recorded
Phase 1	NCT03320642 Background	Feb 2018 → Feb 2021	hematopoietic and lymphoid cell neoplasm	Incyte Corporation	Terminated	No outcome recorded
Phase 1	NCT02122081 Background	Jul 2015 → Sep 2022	acute myeloid leukemia with 11q23 abnormalities, acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22), acute myeloid leukemia with t(8;21)(q22;q22) translocation, acute promyelocytic leukemia +2	Sumithira Vasu	Completed	No outcome recorded
Phase 1	NCT02129582 Background	Nov 2014 → Mar 2019	B-cell chronic lymphocytic leukemia, Hodgkins lymphoma, acute myeloid leukemia, chronic myeloid leukemia +3	Case Comprehensive Cancer Center	Completed	No outcome recorded
Phase 1	NCT02083250 Background	Mar 2014 → Nov 2021	acute lymphoblastic leukemia, acute myeloid leukemia, disease related to hematopoietic stem cell transplant, myelodysplastic syndrome	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 1	NCT01758328 Background	Dec 2012 → Mar 2025	plasma cell myeloma	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 1	NCT00890500 Comparator	Jan 2011 → May 2013	disease related to hematopoietic stem cell transplant, hematopoietic and lymphoid cell neoplasm	Fate Therapeutics	Completed	No outcome recorded
Phase 1	NCT00880815 Background	Feb 2009 → May 2019	T-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma +2	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 1	NCT00354419 Background	Feb 2006 → Dec 2010	aplastic anemia	Fred Hutchinson Cancer Center	Terminated	No outcome recorded
Phase 1	NCT00376480 Background	Jun 2005 → Jun 2010	leukemia, myelodysplastic syndrome	Dana-Farber Cancer Institute	Completed	No outcome recorded
Phase 1	NCT00112645 Background	Apr 2005 → Apr 2010	childhood malignant neoplasm, neuroblastoma, sarcoma	Milton S. Hershey Medical Center	Completed	No outcome recorded
Phase 1	NCT00304018 Background	Oct 2002 → Mar 2009	leukemia, myelodysplastic syndrome, plasma cell neoplasm	University of California, San Francisco	Completed	No outcome recorded
Phase 1	NCT01020539 Background	Sep 2002 → Jul 2011	acute myeloid leukemia, juvenile myelomonocytic leukemia, myelodysplastic syndrome	Columbia University	Completed	No outcome recorded
Phase 1	NCT00054236 Background	May 2002 → Mar 2011	leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloproliferative neoplasm +1	Case Comprehensive Cancer Center	Completed	No outcome recorded
Phase 1	NCT00854139 Background	Aug 2001 → Jul 2014	end stage renal failure, plasma cell myeloma	Massachusetts General Hospital	Completed	No outcome recorded
Phase 1	NCT00004904 Background	Oct 1999 → Jul 2000	graft versus host disease, leukemia, myelodysplastic syndrome, myeloproliferative neoplasm +3	Northwestern University	Completed	No outcome recorded
Phase 1	NCT00003435 Background	May 1998 → ?	leukemia, lymphoma	Duke University	Withdrawn	No outcome recorded

Phase 1/219 trials
Phase 1/2	NCT07061574 Comparator	Mar 2026 → Apr 2030 expected	type 1 diabetes mellitus	City of Hope Medical Center	Recruiting	No outcome recorded
Phase 1/2	NCT06279494 Background	Mar → Jun 2024	acute leukemia, aplastic anemia, myelodysplastic syndrome	Peking University People's Hospital	Unknown	No outcome recorded
Phase 1/2	NCT04224558 Background	Nov 2019 → Sep 2027 expected	Crohn disease	Cedars-Sinai Medical Center	Recruiting	No outcome recorded
Phase 1/2	NCT03622788 Background	Aug 2019 → Dec 2027 expected	Hodgkins lymphoma, acute myeloid leukemia, aplastic anemia, bone marrow failure syndrome +6	M.D. Anderson Cancer Center	Active not recruiting	No outcome recorded
Phase 1/2	NCT02014506 Background	Jan 2017 → Dec 2018	cancer, disease related to hematopoietic stem cell transplant	Asan Medical Center	Unknown	No outcome recorded
Phase 1/2	NCT02821026 Background	May 2016 → Nov 2019	type 1 diabetes mellitus	University of Alberta	Completed	No outcome recorded
Phase 1/2	NCT02561767 Background	Oct 2015 → Oct 2016	acute kidney tubular necrosis	First Affiliated Hospital, Sun Yat-Sen University	Unknown	No outcome recorded
Phase 1/2	NCT01629511 Background	Nov 2012 → Apr 2018	B-cell chronic lymphocytic leukemia, Richter transformation, disease related to hematopoietic stem cell transplant, prolymphocytic leukemia	M.D. Anderson Cancer Center	Terminated	No outcome recorded
Phase 1/2	NCT01664910 Background	Oct 2012 → Jun 2023	hematopoietic and lymphoid cell neoplasm	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT01701986 Background	Oct 2012 → Jun 2024	B-cell non-Hodgkin lymphoma, Hodgkins lymphoma, T-cell non-Hodgkin lymphoma, disease related to hematopoietic stem cell transplant	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT01623167 Background	Jul 2012 → Jan 2018 overdue	aplastic anemia	National Heart, Lung, and Blood Institute (NHLBI)	Active not recruiting	No outcome recorded
Phase 1/2	NCT01154387 Comparator	Jul 2010 → Jun 2013	end stage renal failure	Tolera Therapeutics, Inc	Unknown	No outcome recorded
Phase 1/2	NCT00672204 Background	Nov 2007 → Dec 2010	hypoglycemia, type 1 diabetes mellitus	University of Minnesota	Terminated	No outcome recorded
Phase 1/2	NCT01346085 Background	Oct 2006 → Jun 2009	type 1 diabetes mellitus	Ospedale San Raffaele	Completed	No outcome recorded
Phase 1/2	NCT00286624 Background	Mar 2003 → Aug 2006	hypoglycemia, type 1 diabetes mellitus	University of Minnesota	Completed	No outcome recorded
Phase 1/2	NCT00038831 Background	May 2001 → Mar 2005	acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, myelodysplastic syndrome	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT00281983 Background	Jun 2000 → Jul 2010	B-cell chronic lymphocytic leukemia	German CLL Study Group	Completed	No outcome recorded
Phase 1/2	NCT00995059 Background	—	plasma cell myeloma	Mayo Clinic	Withdrawn	No outcome recorded
Phase 1/2	NCT00228852 Background	? → Nov 2006	T-cell immunodeficiency, severe combined immunodeficiency	Emory University	Completed	No outcome recorded

Phase 297 trials
Phase 2	NCT07001254 Background	Aug 2026 → Dec 2031 expected	aplastic anemia	Anjali Sharathkumar	Not yet recruiting	No outcome recorded
Phase 2	NCT07284641 Background	May 2026 → May 2030 expected	DiGeorge syndrome, GATA2 deficiency with susceptibility to MDS/AML, Omenn syndrome, STAT3-related early-onset multisystem autoimmune disease +8	Paul Szabolcs	Recruiting	No outcome recorded
Phase 2	NCT06517641 Comparator	May 2025 → Aug 2028 expected	aplastic anemia	Medical College of Wisconsin	Recruiting	No outcome recorded
Phase 2	NCT06055608 Background	May 2024 → Jun 2028 expected	—	National Institute of Allergy and Infectious Diseases (NIAID)	Recruiting	No outcome recorded
Phase 2	NCT06334367 Background	Mar 2024 → Mar 2026	graft versus host disease	Wang Xin	Unknown	No outcome recorded
Phase 2	NCT06075706 Comparator	Nov 2023 → Feb 2026 overdue	acute graft versus host disease	medac GmbH	Active not recruiting	No outcome recorded
Phase 2	NCT05323617 Background	Aug 2023 → Feb 2025	aplastic anemia	Amgen	Withdrawn	No outcome recorded
Phase 2	NCT05156710 Background	Jun 2022 → Oct 2025 overdue	transplant rejection	Sanofi	Active not recruiting	No outcome recorded
Phase 2	NCT04118556 Comparator	Dec 2021 → Apr 2026	acute graft versus host disease	Mats Remberger	Terminated	No outcome recorded
Phase 2	NCT04311632 Comparator	May 2021 → Oct 2023	—	ITB-Med LLC	Completed	No outcome recorded
Phase 2	NCT04558736 Background	Jan 2021 → Jul 2029 expected	aplastic anemia, bone marrow failure syndrome	St. Jude Children's Research Hospital	Recruiting	No outcome recorded
Phase 2	NCT03922724 Background	Apr 2019 → Jun 2027 expected	lymphoproliferative syndrome, peripheral T-cell lymphoma, not otherwise specified	National Cancer Institute (NCI)	Recruiting	No outcome recorded
Phase 2	NCT03734601 Background	Nov 2018 → Dec 2019	Hodgkins lymphoma, T-cell non-Hodgkin lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma +2	Stanford University	Completed	No outcome recorded
Phase 2	NCT03630211 Background	Jul 2018 → Aug 2026 overdue	diffuse scleroderma, interstitial lung disease, pulmonary hypertension	Paul Szabolcs	Recruiting	No outcome recorded
Phase 2	NCT03955601 Background	Jul 2018 → Dec 2020	idiopathic aplastic anemia	National Institute of Blood and Marrow Transplant (NIBMT), Pakistan	Unknown	No outcome recorded
Phase 2	NCT03096782 Background	Oct 2017 → Sep 2022	Hodgkins lymphoma, Langerhans cell histiocytosis, acute biphenotypic leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma +3	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT03025698 Background	Sep 2017 → Apr 2022	aplastic anemia	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT02918292 Background	Jul 2017 → Aug 2021	aplastic anemia	Medical College of Wisconsin	Completed	No outcome recorded
Phase 2	NCT02876679 Comparator	Apr 2017 → Oct 2020	graft versus host disease	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 2	NCT02727803 Background	May 2016 → May 2027 expected	B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), Hodgkins lymphoma, acute biphenotypic leukemia, acute myeloid leukemia with multilineage dysplasia +7	M.D. Anderson Cancer Center	Recruiting	No outcome recorded
Phase 2	NCT02702960 Background	Mar 2016 → Jan 2018	fibrolamellar hepatocellular carcinoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Withdrawn	No outcome recorded
Phase 2	NCT02462252 Background	Oct 2015 → Nov 2020	aplastic anemia, myelodysplastic syndrome	BioLineRx, Ltd.	Completed	No outcome recorded
Phase 2	NCT02424968 Background	Jun 2015 → Jul 2020	B-cell chronic lymphocytic leukemia, Hodgkins lymphoma, T-cell non-Hodgkin lymphoma, acute myeloid leukemia +1	Robert Lowsky	Completed	No outcome recorded
Phase 2	NCT02029638 Background	Jan 2014 → Sep 2017	—	National Institute of Allergy and Infectious Diseases (NIAID)	Terminated	No outcome recorded
Phase 2	NCT01861106 Comparator	Jul 2013 → Dec 2027 expected	GATA2 deficiency with susceptibility to MDS/AML, myelodysplastic syndrome	National Cancer Institute (NCI)	Recruiting	No outcome recorded
Phase 2	NCT01811368 Background	Mar 2013 → Apr 2023	non-Hodgkin lymphoma	Joseph Tuscano	Unknown	No outcome recorded
Phase 2	NCT01895244 Background	Sep 2012 → Sep 2021	systemic sclerosis	University Hospital Tuebingen	Completed	No outcome recorded
Phase 2	NCT01759732 Background	Sep 2012 → Dec 2014	acquired aplastic anemia	Asan Medical Center	Unknown	No outcome recorded
Phase 2	NCT01534143 Background	Feb 2012 → May 2013	plasma cell myeloma	Barbara Ann Karmanos Cancer Institute	Terminated	No outcome recorded
Phase 2	NCT01390402 Background	Jan 2012 → Nov 2014	chronic myeloid leukemia	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT01370213 Background	Sep 2011 → Apr 2016	acute myeloid leukemia, myelodysplastic syndrome	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 2	NCT01020734 Background	May 2011 → Jul 2015	leukemia	Asan Medical Center	Completed	No outcome recorded
Phase 2	NCT00448201 Comparator	Jan 2011	leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, plasma cell neoplasm	UNC Lineberger Comprehensive Cancer Center	Completed	No outcome recorded
Phase 2	NCT01118013 Background	Dec 2010 → Mar 2012	immunoproliferative disorder, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm +1	Alliance for Clinical Trials in Oncology	Terminated	No outcome recorded
Phase 2	NCT01168219 Background	Jul 2010 → Nov 2015	acute megakaryoblastic leukemia in adult, acute myeloblastic leukemia with maturation, acute myeloblastic leukemia without maturation, acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent +9	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT01359254 Background	Apr 2010 → Sep 2011	hematologic disorder	University of Chicago	Terminated	No outcome recorded
Phase 2	NCT01044745 Background	Dec 2009 → Dec 2012	Burkitt lymphoma, MALT lymphoma, Waldenstrom macroglobulinemia, acute myeloid leukemia +14	University of Nebraska	Terminated	No outcome recorded
Phase 2	NCT00863148 Background	Oct 2009 → Jun 2013	acute myeloid leukemia, myelodysplastic syndrome	Nantes University Hospital	Completed	No outcome recorded
Phase 2	NCT00919503 Background	Jul 2009 → Jun 2020	hematologic disorder	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 2	NCT01375023 Background	Jun 2009 → Jul 2013	breast cancer	European Institute of Oncology	Terminated	No outcome recorded
Phase 2	NCT00882895 Background	May 2009 → Jun 2028 expected	non-Hodgkin lymphoma	Washington University School of Medicine	Active not recruiting	No outcome recorded
Phase 2	NCT00896493 Background	May 2009 → Nov 2021	Sezary syndrome, bone marrow failure syndrome, fungal infectious disease, primary cutaneous T-cell lymphoma	Stanford University	Completed	No outcome recorded
Phase 2	NCT01071239 Background	Apr 2009 → Aug 2016	Fanconi anemia	Medical College of Wisconsin	Completed	No outcome recorded
Phase 2	NCT00789308 Background	Jul 2008 → Jul 2013	type 1 diabetes mellitus	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00489281 Background	Jun 2008 → Dec 2018	sickle cell disease	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Terminated	No outcome recorded
Phase 2	NCT00629798 Background	Feb 2008 → Oct 2020	acute myeloid leukemia, myelodysplastic syndrome	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 2	NCT00740467 Background	Jan 2008 → Jan 2010	graft versus host disease, leukemia, plasma cell neoplasm, precancerous condition	Institut Paoli-Calmettes	Unknown	No outcome recorded
Phase 2	NCT00603954 Comparator	Jan 2008 → Jul 2016	hematopoietic and lymphoid cell neoplasm	University of Liege	Completed	No outcome recorded
Phase 2	NCT00553202 Background	Jan 2008 → Jun 2016	leukemia	Children's Oncology Group	Completed	No outcome recorded
Phase 2	NCT00720629 Comparator	Dec 2007 → Dec 2013	graft versus host disease	H. Lee Moffitt Cancer Center and Research Institute	Terminated	No outcome recorded
Phase 2	NCT01093586 Background	Sep 2007 → Dec 2015	B-cell adult acute lymphocytic leukemia, B-cell childhood acute lymphoblastic leukemia, Burkitt lymphoma, MALT lymphoma +31	Case Comprehensive Cancer Center	Completed	No outcome recorded
Phase 2	NCT00439556 Background	Feb 2007 → Jun 2018	lymphoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00481832 Background	Jan 2007 → Oct 2014	non-Hodgkin lymphoma	Stanford University	Terminated	No outcome recorded
Phase 2	NCT00464555 Background	Dec 2006 → Nov 2011	type 1 diabetes mellitus	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00425802 Background	Nov 2006 → Oct 2016	leukemia, lymphoma	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 2	NCT00468442 Background	Nov 2006 → Sep 2011	type 1 diabetes mellitus	National Institute of Allergy and Infectious Diseases (NIAID)	Terminated	No outcome recorded
Phase 2	NCT00482053 Background	Oct 2006 → May 2010	diffuse large B-cell lymphoma	Stanford University	Terminated	No outcome recorded
Phase 2	NCT00434850 Background	Oct 2006 → Sep 2011	type 1 diabetes mellitus	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00827099 Background	Jun 2006 → Nov 2009	leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, plasma cell neoplasm	Northside Hospital, Inc.	Terminated	No outcome recorded
Phase 2	NCT00281879 Comparator	Feb 2006 → Feb 2008	childhood malignant neoplasm, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm +1	OHSU Knight Cancer Institute	Terminated	No outcome recorded
Phase 2	NCT00343785 Background	Feb 2006 → May 2012	aplastic anemia	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00133367 Background	Aug 2005 → Nov 2007	Hodgkins lymphoma, myeloid leukemia, non-Hodgkin lymphoma, plasma cell myeloma +1	Massachusetts General Hospital	Completed	No outcome recorded
Phase 2	NCT00392782 Background	Jul 2005 → May 2011	leukemia, myelodysplastic syndrome	Masonic Cancer Center, University of Minnesota	Terminated	No outcome recorded
Phase 2	NCT00385788 Background	Jul 2005 → Aug 2016	Hodgkins lymphoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00305682 Comparator	Jun 2005 → Dec 2019	leukemia, lymphoma, myelodysplastic syndrome, myeloproliferative neoplasm	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 2	NCT00795132 Comparator	Apr 2004 → Jul 2009	acute leukemia, lymphoma, myelodysplastic syndrome	University of Utah	Completed	No outcome recorded
Phase 2	NCT00070135 Background	Jan 2004 → Dec 2013	acute myeloid leukemia	Alliance for Clinical Trials in Oncology	Completed	No outcome recorded
Phase 2	NCT00084695 Background	Sep 2003 → Dec 2012	Fanconi anemia, Langerhans cell histiocytosis specific to childhood, childhood malignant neoplasm, leukemia +4	Milton S. Hershey Medical Center	Unknown	No outcome recorded
Phase 2	NCT00061360 Background	Jun 2003 → Feb 2006	aplastic anemia	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 2	NCT00185640 Background	Mar 2003 → Apr 2014	leukemia	Stanford University	Completed	No outcome recorded
Phase 2	NCT00499889 Background	Feb 2003 → Nov 2009	leukemia	M.D. Anderson Cancer Center	Terminated	No outcome recorded
Phase 2	NCT00627666 Background	Jan 2003 → Jun 2010	leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm	Asan Medical Center	Completed	No outcome recorded
Phase 2	NCT00055653 Background	Jan → Sep 2003	leukemia, lymphoma, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease	Roswell Park Cancer Institute	Completed	No outcome recorded
Phase 2	NCT00188136 Background	Aug 2002 → Jul 2010	acute myeloid leukemia	University Hospital Carl Gustav Carus	Completed	No outcome recorded
Phase 2	NCT00176865 Comparator	Aug 2002 → Aug 2012	Chediak-Higashi syndrome, Griscelli syndrome, Langerhans cell histiocytosis, X-linked lymphoproliferative syndrome	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 2	NCT00258427 Background	Mar 2002 → Oct 2020	Fanconi anemia	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 2	NCT00053989 Background	Jan 2002 → Jul 2018	Fanconi anemia, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease +2	Roswell Park Cancer Institute	Completed	No outcome recorded
Phase 2	NCT00262886 Background	Aug 2001 → Jul 2007	kidney cancer	University of Rochester	Completed	No outcome recorded
Phase 2	NCT00024128 Background	Aug 2001 → Mar 2003	lymphoma	AIDS Malignancy Consortium	Withdrawn	No outcome recorded
Phase 2	NCT00028730 Background	Aug 2001 → Jul 2006	leukemia, lymphoma, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 2	NCT00025038 Background	Jun 2001 → Oct 2007	juvenile myelomonocytic leukemia	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00185692 Background	Aug 2000 → Dec 2010	B-cell chronic lymphocytic leukemia, Hodgkins lymphoma, cancer, graft versus host disease +1	Stanford University	Completed	No outcome recorded
Phase 2	NCT00006379 Background	Jun 2000 → Jan 2004	leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloproliferative neoplasm +2	Case Comprehensive Cancer Center	Completed	No outcome recorded
Phase 2	NCT00040482 Background	Apr 1999 → Aug 2005	multiple sclerosis	Baylor College of Medicine	Completed	No outcome recorded
Phase 2	NCT00004145 Background	Nov 1998 → Nov 2003	leukemia, myelodysplastic syndrome, plasma cell neoplasm	University of Chicago	Completed	No outcome recorded
Phase 2	NCT00003396 Background	Sep 1998 → Dec 2002	leukemia, myelodysplastic syndrome, plasma cell neoplasm	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 2	NCT00003662 Background	Aug 1998 → Jan 2001	graft versus host disease, leukemia, myelodysplastic syndrome, thymic carcinoma	Roswell Park Cancer Institute	Completed	No outcome recorded
Phase 2	NCT00003661 Background	Jun 1998 → Nov 1999	graft versus host disease, leukemia, lymphoma, myelodysplastic syndrome +1	Roswell Park Cancer Institute	Completed	No outcome recorded
Phase 2	NCT00008307 Background	Apr 1998 → ?	leukemia, myelodysplastic syndrome, plasma cell neoplasm	Herbert Irving Comprehensive Cancer Center	Unknown	No outcome recorded
Phase 2	NCT00003336 Background	Jan 1998 → Dec 2005	leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease	Case Comprehensive Cancer Center	Completed	No outcome recorded
Phase 2	NCT00003335 Background	Jan 1998 → Nov 2007	graft versus host disease, leukemia, lymphoma, myelodysplastic syndrome +1	Case Comprehensive Cancer Center	Completed	No outcome recorded
Phase 2	NCT00003270 Background	Sep 1997 → Oct 2017	graft versus host disease, leukemia, myelodysplastic syndrome, plasma cell neoplasm	Roswell Park Cancer Institute	Completed	No outcome recorded
Phase 2	NCT00005641 Background	Sep 1997 → Sep 2000	graft versus host disease, leukemia, myelodysplastic syndrome, myeloproliferative neoplasm +1	H. Lee Moffitt Cancer Center and Research Institute	Terminated	No outcome recorded
Phase 2	NCT00002809 Background	Aug 1996 → Dec 2003	leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease	Temple University	Completed	No outcome recorded
Phase 2	NCT00002718 Background	Nov 1995 → Jan 2004	leukemia, lymphoma, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 2	NCT00004323 Background	Feb 1995 → ?	aplastic anemia	National Center for Research Resources (NCRR)	Completed	No outcome recorded
Phase 2	NCT00101140 Background	—	acute erythroid leukemia	Eastern Cooperative Oncology Group	Withdrawn	No outcome recorded

Phase 2/37 trials
Phase 2/3	NCT01949129 Background	Apr 2013 → Jun 2025 overdue	acute lymphoblastic leukemia	St. Anna Children's Cancer Research	Recruiting	No outcome recorded
Phase 2/3	NCT01751997 Comparator	Jan 2013 → May 2019	acute myeloid leukemia	Byung-Sik Cho	Completed	No outcome recorded
Phase 2/3	NCT01087398 Background	Sep 2009 → Nov 2012	osteopetrosis	Tehran University of Medical Sciences	Unknown	No outcome recorded
Phase 2/3	NCT00455312 Background	Aug 2007 → Mar 2015	aplastic anemia, dyskeratosis congenita	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 2/3	NCT00176878 Background	Jun 2000 → Mar 2009	Diamond-Blackfan anemia, Kostmann syndrome, Shwachman-Diamond syndrome	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 2/3	NCT00004255 Background	Mar 2000 → May 2003	graft versus host disease, leukemia, myelodysplastic syndrome	Chimeric Therapies	Completed	No outcome recorded
Phase 2/3	NCT00176904 Background	Jan 1995 → Jun 2010	GM1 gangliosidosis, Gaucher disease, Krabbe disease, Niemann-Pick disease +6	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded

Phase 312 trials
Phase 3	NCT05600426 Comparator	Jan 2023 → Dec 2029 expected	aplastic anemia	Boston Children's Hospital	Active not recruiting	No outcome recorded
Phase 3	NCT04629833 Comparator	Aug 2021 → Aug 2027 expected	acute graft versus host disease	medac GmbH	Recruiting	No outcome recorded
Phase 3	NCT04945096 Background	Jul 2021 → Jul 2025	graft versus host disease	The First Affiliated Hospital of Soochow University	Unknown	No outcome recorded
Phase 3	NCT03413306 Background	Dec 2016 → Oct 2022	acquired aplastic anemia	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	Unknown	No outcome recorded
Phase 3	NCT02099747 Background	Jul 2015 → Dec 2020	aplastic anemia	European Society for Blood and Marrow Transplantation	Completed	No outcome recorded
Phase 3	NCT00568633 Background	Aug 2007 → Dec 2015	acute myeloid leukemia	Stanford University	Terminated	No outcome recorded
Phase 3	NCT00468117 Background	Jan 2007 → Jul 2015	type 1 diabetes mellitus	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00434811 Background	Oct 2006 → Sep 2012	type 1 diabetes mellitus	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00334672 Background	Mar 2006 → Nov 2010	—	Children's Cancer and Leukaemia Group	Unknown	No outcome recorded
Phase 3	NCT00004208 Comparator	Aug 2000 → Oct 2006	myelodysplastic syndrome	Swiss Cancer Institute	Completed	No outcome recorded
Phase 3	NCT00006451 Background	Apr 1996 → Nov 2000	graft versus host disease, leukemia, lymphoma	Masonic Cancer Center, University of Minnesota	Withdrawn	No outcome recorded
Phase 3	NCT00002534 Background	May 1993 → Apr 2003	leukemia	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded

Phase 47 trials
Phase 4	NCT07648992 Comparator	Dec 2025 → Dec 2029 expected	disease related to hematopoietic stem cell transplant	Daihong Liu	Recruiting	No outcome recorded
Phase 4	NCT06069180 Background	Nov 2023 → Dec 2024	aplastic anemia	Peking University People's Hospital	Unknown	No outcome recorded
Phase 4	NCT03689465 Comparator	Oct 2018 → Sep 2020	disease related to hematopoietic stem cell transplant	Nanfang Hospital, Southern Medical University	Unknown	No outcome recorded
Phase 4	NCT01266148 Background	Nov 2009 → Dec 2012	—	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00331162 Comparator	Feb 2005 → Nov 2011	transplant rejection	Wake Forest University Health Sciences	Completed	No outcome recorded
Phase 4	NCT00275535 Comparator	Apr 2001 → Nov 2007	kidney disorder	Mayo Clinic	Completed	No outcome recorded
Phase 4	NCT00003398 Background	Sep 1998 → May 2000	anemia, graft versus host disease, leukemia, myelodysplastic syndrome +1	University of Maryland, Baltimore	Completed	No outcome recorded

Phase not applicable18 trials
—	NCT07588360 Background	Oct 2025 → Oct 2028 expected	acute myeloid leukemia, myelodysplastic syndrome	Fujian Medical University Union Hospital	Recruiting	No outcome recorded
—	NCT02845596 Comparator	Aug 2016 → Nov 2020	acquired aplastic anemia	Michael Pulsipher	Completed	No outcome recorded
—	NCT02158052 Background	Feb 2015 → Jun 2021	amyloidosis, plasma cell myeloma	Massachusetts General Hospital	Completed	No outcome recorded
—	NCT01685411 Background	Jan 2013 → Feb 2020	acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome	Masonic Cancer Center, University of Minnesota	Terminated	No outcome recorded
—	NCT01598025 Background	May 2012 → Oct 2017	acute leukemia, chronic leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma	Memorial Sloan Kettering Cancer Center	Terminated	No outcome recorded
—	NCT00550992 Background	Jan 2006 → Dec 2020	leukemia	Dutch Childhood Oncology Group	Unknown	No outcome recorded
—	NCT00608517 Background	Sep 2005 → Mar 2008	graft versus host disease, leukemia, myelodysplastic syndrome, plasma cell neoplasm	Vanderbilt-Ingram Cancer Center	Terminated	No outcome recorded
—	NCT00295997 Background	May 2005 → ?	kidney cancer, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm +1	University of California, San Francisco	Unknown	No outcome recorded
—	NCT00317408 Background	Apr 2004 → Feb 2014	lymphoma	European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma	Unknown	No outcome recorded
—	NCT00521430 Background	Apr 2004 → May 2008	benign neoplasm, leukemia, myelodysplastic syndrome, plasma cell neoplasm	Asan Medical Center	Completed	No outcome recorded
—	NCT00068523 Background	Jun 2003 → Mar 2004	leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloproliferative neoplasm +1	Case Comprehensive Cancer Center	Completed	No outcome recorded
—	NCT00017654 Background	Apr 2001 → ?	aplastic anemia, graft versus host disease	Northwestern Memorial Hospital	Unknown	No outcome recorded
—	NCT00005893 Background	Jun 2000 → ?	beta-thalassemia major, neutropenia, pure red-cell aplasia, sickle cell disease	Fairview University Medical Center	Completed	No outcome recorded
—	NCT00006056 Background	Mar 2000 → ?	Chediak-Higashi syndrome, X-linked lymphoproliferative syndrome, graft versus host disease, secondary hemophagocytic lymphohistiocytosis	Fairview University Medical Center	Unknown	No outcome recorded
—	NCT00006055 Background	Mar 2000 → ?	Takayasu arteritis, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, eosinophilic granulomatosis with polyangiitis +8	Fairview University Medical Center	Unknown	No outcome recorded
—	NCT00290628 Background	Oct 1999 → Apr 2007	Diamond-Blackfan anemia, Fanconi anemia, graft versus host disease, leukemia +4	Masonic Cancer Center, University of Minnesota	Terminated	No outcome recorded
—	NCT00296023 Background	Jan 1999 → Jun 2007	leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, plasma cell neoplasm	University of California, San Francisco	Completed	No outcome recorded
—	NCT00409461 Background	—	type 1 diabetes mellitus	University Hospital Brussels	Terminated	No outcome recorded

Evidence & citations 36 cited values

Every value below carries the sentence it was read from. 298 sources stand behind the page.

Field	Value	Cited text
Known as	ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)	ChEMBL registry synonym — accepted as the source's own label CHEMBL2108981 ↗
Known as	Anti-human thymocyte immunoglobulin, equine	ChEMBL registry synonym — accepted as the source's own label CHEMBL2108981 ↗
Known as	Anti-thymocyte globulin (ATG)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05579769 ↗ 7 NCT00176865 ↗ NCT00720629 ↗ NCT03734601 ↗ NCT07061574 ↗ NCT00972101 ↗ NCT00568633 ↗ NCT01359254 ↗
Known as	Anti-thymocyte globulin equine	ChEMBL registry synonym — accepted as the source's own label CHEMBL2108981 ↗
Known as	antithymocyte globulin	“The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG),...” NCT04118556 ↗ 260 “A conditioning regimen for allogeneic hematopoietic cell transplantation (HCT) combining total lymphoid irradiation (TLI) plus anti-thymocyte globulin (ATG) has been developed...” PMID 25779951 ↗ Mar 2015 “All patients received cyclophosphamide (CY), single fraction total body irradiation (TBI), and antithymocyte globulin (ATG) with or without fludarabine (FLU), followed by...” PMID 25824692 ↗ Mar 2015 “Participants will receive any one of the following systemic BATs based on the Investigator's decision: mycophenolate mofetil (MMF), extracorporeal photopheresis (ECP),...” NCT04629833 ↗ “Anti-thymocyte globulin (ATG-rabbit, Thymoglobuline®) 0.5 mg/kg body weight iv on day -5, 1.0 mg ATG-rabbit/kg will be given iv on day -4, and 1.5 mg ATG-rabbit /kg will be...” NCT03477500 ↗ “Antithymocyte globulin (ATG Fresenius 10 mg/kg/day day -5 to -2, total dose 40 mg/kg, Fresenius, Bad Homburg, Germany) will be applied after transplantation from unrelated or...” NCT00188136 ↗ “Because sirolimus (SIR) monotherapy was successful in kidney transplantation under antithymocyte globulin (ATG), we undertook a pilot study comparing SIR monotherapy with...” PMID 18212631 ↗ Jan 2008 “low dose Antithymocyte Globulin plus low dose post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation” NCT03608059 ↗ “Anti-thymocyte globulin (ATG) is widely used in allogeneic hematopoietic stem cell transplantation (allo-HCT) to prevent severe graft-versus-host disease (GVHD) and graft failure.” PMID 41624481 ↗ Apr 2025 “Anti-Thymocyte Globulin, rabbit (r-ATG, Thymoglobulin®) is a polyclonal antibody against T-lymphocytes that is used for the prevention and treatment of acute allograft rejection.” NCT00331162 ↗ “We evaluated the role of granulocyte colony-stimulating factor (G-CSF) in patients with severe aplastic anemia (SAA) treated with antithymocyte globulin (ATG) and cyclosporine.” PMID 21233311 ↗ Jan 2011 “Anti-thymocyte globulin (ATG) is widely used in allogeneic hematopoietic stem cell transplantation to prevent severe graft-versus-host disease (GVHD) and graft failure.” PMID 37706580 ↗ Sep 2023 “Antithymocyte globulin may be included at the treating investigator's discretion with the tacrolimus/methotrexate or cyclosporine A/mycophenolate mofetil combinations.” NCT03320642 ↗ “Anti-thymocyte globulin (ATG) preparative regimen in the setting of haploidentical stem cell transplantation (haplo-HSCT) is vital for inducing immune tolerance.” NCT03631563 ↗ “The CloB2A2 regimen consisted of clofarabine 30 mg/m(2)/day for 4 days, busulfan 3.2 mg/kg/day for 2 days and antithymocyte globulin 2.5 mg/kg/day for 2 days.” PMID 24951467 ↗ Jun 2014 “Treatment of Severe Aplastic Anemia With Combined Immunosuppression: Antithymocyte Globulin (ATG) and Cyclosporine A (CSA), and Mycophenolate Mofetil (MMF)” NCT00001964 ↗ “The optimal dose of rabbit antithymocyte globulin (ATG, ImtixSangstat) minimizing infections without increasing graft-versus-host disease (GVHD) is unknown” PMID 31401973 ↗ Aug 2019 “Our previous studies have shown that reduced-dose anti-thymocyte globulin(ATG) in the conditioning regimen can achieve the same effect as full-dose ATG.” NCT06334367 ↗ “and anti-thymocyte globulin (ATG- a non-chemotherapy drug whose role is to kill your immune system) for the treatment of patients with Fanconi anemia” NCT01071239 ↗ “Frame shifting anti-thymocyte globulin (ATG) backwards to earlier days before days 0 can result in deeper host and less graft T-cell depletion” NCT06265584 ↗ “anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib.” NCT05132166 ↗ “conditioning regimen of alemtuzumab/Campath, anti-thymocyte globulin/rabbit ATG, Fludarabine and Melphalan and total body irradiation” NCT07284641 ↗ “Anti-thymocyte globulin (ATG) and alemtuzumab (Campath) are anti-rejection medications that work by decreasing a patient's T-cells.” NCT01909245 ↗ “Antithymocyte Globulin (ATG) dose will be 0.5 mg/kg IV on Day -9 over 6 hours and 2 mg/kg IV on Days -8 and -7 over 4 hours.” NCT06517641 ↗ “TLI (Total Lymphoid Irradiation)/single low dose Total Body Irradiation, ATG (Anti-Thymocyte Globulin) conditioning” NCT04571203 ↗ “extracorporeal photopheresis (ECP), anti-thymocyte globulin (ATG), etanercept, infliximab or ruxolitinib (RUX)” NCT06075706 ↗ “A growing body of studies have suggested antithymocyte globulin (ATG) could reduce the incidence of cGVHD.” NCT04203108 ↗ “induction therapy with anti-thymocyte globulin (ATG) instead of anti-interleukin-2Ra monoclonal antibody” PMID 25286053 ↗ Dec 2014 “Antithymocyteglobulin (ATG) has been widely used to prevent acute GVHD (aGVHD) in haploidentical HSCT.” NCT02643589 ↗ “ATG (anti-thymocyte globulin, rabbit; 5 mg/kg, day -5 to -2) was used in matched sibling donor-HSCT.” NCT06238245 ↗ “antithymocyte globulin (ATG; immune proteins made in horses that, when given, will kill lymphocytes)” NCT00228852 ↗ “Cyclophosphamide (Cy)/anti-thymocyte globulin (ATG) is considered the standard conditioning regimen” NCT03295058 ↗ “rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France).” NCT03412266 ↗ “rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France)” NCT03412409 ↗ “Therapy of Myelodysplastic Syndrome (MDS) With Antithymocyte Globulin (ATG) and TNFR:Fc” NCT00005853 ↗ “Antithymocyte globulin is administered by IV over at least 4 hours on days -4 to -1.” NCT00003398 ↗ “Antithymocyte Globulin 2 mg/kg IV for 2 days before stem cell transplantation” NCT00385788 ↗ “Antithymocyte globulin (ATG); 1.25 mg/kg/day, IV for 6 hours, days -3 to -2” NCT01751997 ↗ “''rabbit Antithymocyte globulin'' 5 mg /kg/day from day -6 to day-3” NCT03955601 ↗ “Mérieux; horse antithymocyte globulin (ATG) + Cyclosporine A (CSA)” NCT00004208 ↗ “another drug called (rabbit Anti-thymocyte Globulin [ATG])” NCT06315309 ↗ “ATG, antithymocyte globulin; Basiliximab, anti-CD25 mAb.” NCT02561767 ↗ “Antithymocyte globulin (ATG) 30 mg/kg IV Days -2 and -1” NCT00176852 ↗ “Anti-thymocyte Globulin (rATG), as Induction Therapy” NCT04311632 ↗ “antithymocyte globulin (ATG) IV once or twice daily” NCT00055653 ↗ “Conditioning with CYC/ antithymocyte globulin (ATG)” NCT01895244 ↗ “low dose antithymocyte globulin rATG(2.5mg/kg/d)” NCT03395860 ↗ “antithymocyte globulin (ATG)-based protocols” NCT03689465 ↗ “Other therapy: anti-thymocyte globulin (ATG)” NCT04761770 ↗ “antithymocyte globulin IV on days -5 to -2” NCT00301860 ↗ “* Anti-thymocyte Globulin (ATG)” NCT00167219 ↗ “* Anti-thymocyte Globulin (ATG)” NCT02179359 ↗ “Anti-thymocyte Globulin (ATG)” NCT01983761 ↗ “Anti-thymocyte Globulin (ATG)” NCT02171104 ↗ “anti-thymocyte globulin (ATG)” NCT06279494 ↗ “antithymocyte globulin (ATG)” NCT01997372 ↗ “antithymocyte globulin (ATG)” NCT00176826 ↗ NCT00290628 ↗ NCT00346359 ↗ NCT00017654 ↗ NCT00017641 ↗ NCT00346151 ↗ NCT00017550 ↗ NCT01390402 ↗ NCT01239563 ↗ NCT02702960 ↗ NCT07648992 ↗ NCT01664910 ↗ NCT00856388 ↗ NCT00016458 ↗ NCT00613561 ↗ NCT00016419 ↗ NCT00697684 ↗ NCT00589563 ↗ NCT00014755 ↗ NCT00008307 ↗ NCT01598025 ↗ NCT00499889 ↗ NCT00716066 ↗ NCT00024128 ↗ NCT00176878 ↗ NCT00176904 ↗ NCT00006451 ↗ NCT00217386 ↗ NCT00489281 ↗ NCT00488436 ↗ NCT00025038 ↗ NCT07634562 ↗ NCT00006379 ↗ NCT00002809 ↗ NCT00343785 ↗ NCT00038831 ↗ NCT02876679 ↗ NCT00002718 ↗ NCT01044745 ↗ NCT00691015 ↗ NCT00617929 ↗ NCT00854139 ↗ NCT01231841 ↗ NCT00719849 ↗ NCT00378768 ↗ NCT03622788 ↗ NCT01056614 ↗ NCT02122081 ↗ NCT00304018 ↗ NCT00003270 ↗ NCT00003335 ↗ NCT00003336 ↗ NCT04558736 ↗ NCT00392782 ↗ NCT00053196 ↗ NCT00001626 ↗ NCT00112645 ↗ NCT03630211 ↗ NCT00006056 ↗ NCT00006055 ↗ NCT00006054 ↗ NCT02487069 ↗ NCT00053989 ↗ NCT00054236 ↗ NCT00093587 ↗ NCT00001749 ↗ NCT05323617 ↗ NCT01266148 ↗ NCT00295971 ↗ NCT00896493 ↗ NCT00054340 ↗ NCT02029638 ↗ NCT00003396 ↗ NCT00303719 ↗ NCT00482053 ↗ NCT00481832 ↗ NCT01685411 ↗ NCT00275535 ↗ NCT00005937 ↗ NCT00995059 ↗ NCT00295997 ↗ NCT00001839 ↗ NCT00005898 ↗ NCT00005893 ↗ NCT00005853 ↗ NCT00185692 ↗ NCT00185640 ↗ NCT00005852 ↗ NCT03096782 ↗ NCT00005641 ↗ NCT00262886 ↗ NCT00672204 ↗ NCT00296023 ↗ NCT00515099 ↗ NCT00354419 ↗ NCT00305708 ↗ NCT07588360 ↗ NCT00055653 ↗ NCT00740467 ↗ NCT00281879 ↗ NCT00627666 ↗ NCT05166967 ↗ NCT00004904 ↗ NCT01534143 ↗ NCT00376480 ↗ NCT01701986 ↗ NCT04778618 ↗ NCT00890500 ↗ NCT00133367 ↗ NCT01093586 ↗ NCT00003435 ↗ NCT00611351 ↗ NCT02821026 ↗ NCT01118013 ↗ NCT01116232 ↗ NCT00317408 ↗ NCT06098326 ↗ NCT00919503 ↗ NCT01509300 ↗ NCT00004474 ↗ NCT00281983 ↗ NCT00004323 ↗ NCT00003398 ↗ NCT02162420 ↗ NCT00468442 ↗ NCT00468117 ↗ NCT02424968 ↗ NCT00434811 ↗ NCT00434850 ↗ NCT00466843 ↗ NCT04098393 ↗ NCT00629798 ↗ NCT00004255 ↗ NCT00521430 ↗ NCT02215200 ↗ NCT00464555 ↗ NCT02083250 ↗ NCT00334672 ↗ NCT00553202 ↗ NCT00084695 ↗ NCT00630253 ↗ NCT00425802 ↗ NCT00305682 ↗ NCT01624805 ↗ NCT00882895 ↗ NCT00004145 ↗ NCT00286624 ↗ NCT02586831 ↗ NCT00003913 ↗ NCT07216391 ↗ NCT00455312 ↗ NCT02727803 ↗ NCT01168219 ↗ NCT01033552 ↗ NCT00028730 ↗ NCT01811368 ↗ NCT00827099 ↗ NCT01020734 ↗ NCT00003816 ↗ NCT00550992 ↗ NCT01020539 ↗ NCT00365287 ↗ NCT00880815 ↗ NCT06455319 ↗ NCT00787761 ↗ NCT01629511 ↗ NCT05156710 ↗ NCT00074269 ↗ NCT00789308 ↗ NCT00427336 ↗ NCT00448201 ↗ NCT00301951 ↗ NCT02918292 ↗ NCT01413100 ↗ NCT00436761 ↗ NCT00635024 ↗ NCT01375023 ↗ NCT02129582 ↗ NCT00003662 ↗ NCT00003661 ↗ NCT00795132 ↗ NCT01105273 ↗ NCT05757310 ↗ NCT04291703 ↗ NCT00101140 ↗ NCT00003552 ↗ NCT00258427 ↗ NCT00070135 ↗ NCT00068523 ↗ NCT03602898 ↗ NCT06069180 ↗ NCT04945096 ↗ NCT06055608 ↗ NCT05303727 ↗ NCT00802113 ↗ NCT01759732 ↗ NCT00802568 ↗ NCT02014506 ↗ NCT00002534 ↗ NCT00301860 ↗ NCT01758328 ↗ NCT00439556 ↗ NCT01154387 ↗ NCT01370213 ↗ NCT00608517 ↗
Known as	Antithymocyte immunoglobulin (horse)	ChEMBL registry synonym — accepted as the source's own label CHEMBL2108981 ↗
Known as	Antithymocyte Serum	“Antithymocyte Serum” NCT02727803 ↗
Known as	ATG	“The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG),...” NCT04118556 ↗ 66 “All patients received cyclophosphamide (CY), single fraction total body irradiation (TBI), and antithymocyte globulin (ATG) with or without fludarabine (FLU), followed by...” PMID 25824692 ↗ Mar 2015 “Participants will receive any one of the following systemic BATs based on the Investigator's decision: mycophenolate mofetil (MMF), extracorporeal photopheresis (ECP),...” NCT04629833 ↗ “The purpose of this study is to determine the effects of the medication antithymocyte globulin (ATG) in adults with MDS and to determine which individuals with MDS are most...” NCT00466843 ↗ “Antithymocyte globulin (ATG Fresenius 10 mg/kg/day day -5 to -2, total dose 40 mg/kg, Fresenius, Bad Homburg, Germany) will be applied after transplantation from unrelated or...” NCT00188136 ↗ “The regimens for prophylaxis of GVHD based on 10mg/kg rabbit anti-human thymocyte immunoglobin (ATG, Thymoglobulin®, Genzyme Polyclonals S.A.S) effectively reduced the...” NCT04778618 ↗ “Because sirolimus (SIR) monotherapy was successful in kidney transplantation under antithymocyte globulin (ATG), we undertook a pilot study comparing SIR monotherapy with...” PMID 18212631 ↗ Jan 2008 “The regimens for prophylaxis of GVHD based on 10mg/kg rabbit anti-human thymocyte immunoglobin (ATG, Thymoglobin®, Genzyme Polyclonals S.A.S) effectively reduced the occurrence...” NCT05166967 ↗ “Patients were randomly assigned to receive anti-thymocyte globulin (ATG) 5 mg/kg plus standard GVHD prophylaxis or PTCy 50 mg/kg/d at days +3 and +4 plus standard GVHD prophylaxis.” PMID 38374026 ↗ Feb 2024 “Induction therapy, Anti Thymocyte Globulin (ATG): 1-2 mg/kg/day during 3-5 days for control and everolimus groups after transplant surgery and prior to randomization.” NCT01266148 ↗ “anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib.” NCT05132166 ↗ “Anti-Thymocyte Globulin (ATG or Thymoglobulin®) will be administered at a dose of 2.5mg/kg (2 infusions, 0.5 and 2mg/kg) Days 1 and 2” NCT02586831 ↗ “Anti-thymocyte globulin (ATG) and alemtuzumab (Campath) are anti-rejection medications that work by decreasing a patient's T-cells.” NCT01909245 ↗ “Antithymocyte Globulin (ATG) dose will be 0.5 mg/kg IV on Day -9 over 6 hours and 2 mg/kg IV on Days -8 and -7 over 4 hours.” NCT06517641 ↗ “TLI (Total Lymphoid Irradiation)/single low dose Total Body Irradiation, ATG (Anti-Thymocyte Globulin) conditioning” NCT04571203 ↗ “Antithymocyte globulin (ATG) will be intravenously administered over two days, with a total of 2 infusion periods.” NCT04291703 ↗ “extracorporeal photopheresis (ECP), anti-thymocyte globulin (ATG), etanercept, infliximab or ruxolitinib (RUX)” NCT06075706 ↗ “Antithymocyteglobulin (ATG) has been widely used to prevent acute GVHD (aGVHD) in haploidentical HSCT.” NCT02643589 ↗ “ATG (anti-thymocyte globulin, rabbit; 5 mg/kg, day -5 to -2) was used in matched sibling donor-HSCT.” NCT06238245 ↗ “Anti-Thymocyte Globulin (ATG) will be administered at a dose of 2.5mg/kg as two divided IV infusions” NCT02215200 ↗ “antithymocyte globulin (ATG; immune proteins made in horses that, when given, will kill lymphocytes)” NCT00228852 ↗ “Fludarabine, Cytarabine, Busulfan, Antithymocyte Globulin (ATG), Melphalan, Cyclophosphamide (CTX)” NCT07588360 ↗ “Antithymocyte globulin (ATG) intravenous infusion: 40mg/kg/day. Infusion over 6 hours on day 1-4.” NCT00005937 ↗ “Therapy of Myelodysplastic Syndrome (MDS) With Antithymocyte Globulin (ATG) and TNFR:Fc” NCT00005853 ↗ “rabbit anti-thymocyte globulin (ATG) IV over at least 8-12 hours on days 1-4” NCT00017550 ↗ “Antithymocyte globulin (ATG); 1.25 mg/kg/day, IV for 6 hours, days -3 to -2” NCT01751997 ↗ “induction therapy with ATG (1.5 mg/kg/day for 4 days starting at day -1)” NCT01346085 ↗ “anti-thymocyte globulin (ATG) IV over at least 4 hours on days -2 to -1” NCT00054236 ↗ “another drug called (rabbit Anti-thymocyte Globulin [ATG])” NCT06315309 ↗ “antithymocyte globulin (ATG) IV once or twice daily” NCT00055653 ↗ “Anti-Thymocyte Globulin is also refered to as ATG.” NCT00613561 ↗ “anti-thymocyte globulin (ATG) IV over 10 hours” NCT00305708 ↗ “anti-thymocyte globulin (ATG) IV over 4 hours” NCT00550992 ↗ “antithymocyte globulin (ATG) IV over 12 hours” NCT00334672 ↗ “antithymocyte globulin (ATG) IV over 10 hours” NCT00003270 ↗ “Other therapy: anti-thymocyte globulin (ATG)” NCT04761770 ↗ “antithymocyte globulin (ATG) IV over 4 hours” NCT00003662 ↗ “antithymocyte globulin (ATG) twice daily” NCT00006054 ↗ “Anti-Thymocyte Globulin, ATG (Rabbit)” NCT07634562 ↗ “* Anti-thymocyte Globulin (ATG)” NCT02179359 ↗ “* Anti-thymocyte Globulin (ATG)” NCT00167219 ↗ “anti-thymocyte globulin (ATG)” NCT06279494 ↗ “Anti-thymocyte globulin (ATG)” NCT00482053 ↗ “Anti-Thymocyte Globulin (ATG)” NCT06055608 ↗ “anti-thymocyte globulin (ATG)” NCT01758328 ↗ “Antithymocyte Globulin (ATG)” NCT07216391 ↗ “Antithymocyte globulin (ATG)” NCT04098393 ↗ “Antithymocyte globulin (ATG)” NCT05156710 ↗ “ATG-Fresenius versus ATG” NCT03631563 ↗ NCT01983761 ↗ NCT01997372 ↗ NCT00040482 ↗ NCT06572462 ↗ NCT00001964 ↗ NCT02561767 ↗ NCT06334367 ↗ NCT01883180 ↗ NCT00004208 ↗ NCT03395860 ↗ NCT03689465 ↗ NCT04203108 ↗ NCT00061360 ↗ NCT03295058 ↗ NCT01163942 ↗ NCT00603954 ↗ NCT06265584 ↗ NCT01071239 ↗
Known as	ATG (Rabbit)	“Anti-thymocyte globulin (ATG-rabbit, Thymoglobuline®) 0.5 mg/kg body weight iv on day -5, 1.0 mg ATG-rabbit/kg will be given iv on day -4, and 1.5 mg ATG-rabbit /kg will be...” NCT03477500 ↗ 1 “Anti-Thymocyte Globulin, ATG (Rabbit)” NCT07634562 ↗
Known as	ATG Fresenius	“Antithymocyte globulin (ATG Fresenius 10 mg/kg/day day -5 to -2, total dose 40 mg/kg, Fresenius, Bad Homburg, Germany) will be applied after transplantation from unrelated or...” NCT00188136 ↗
Known as	ATG Thymoglobulin	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01949129 ↗
Known as	ATGAM	“After leukapheresis, patients will receive an antibody from horses called Atgam (ATG) to help destroy the immune system” NCT00040482 ↗ 4 “Horse ATG (ATGAM) (hATG) is not considered an investigational medicinal product (IMP)” NCT03025698 ↗ “ATG rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg” NCT01087398 ↗ “h-ATG (ATGAM )” NCT00944749 ↗ NCT06972069 ↗
Known as	e-ATG	“equine anti-thymocyte globulin (e-ATG) 40 mg/kg/day IV” NCT03922724 ↗
Known as	Equine anti-thymocyte globulin	“equine anti-thymocyte globulin (e-ATG) 40 mg/kg/day IV” NCT03922724 ↗ 4 NCT04862221 ↗ NCT02158052 ↗ NCT01861106 ↗ NCT00923364 ↗
Known as	Equine thymocyte immune globulin	ChEMBL registry synonym — accepted as the source's own label CHEMBL2108981 ↗
Known as	hATG	“Aplastic anemia can be treated effectively with allogeneic bone marrow transplantation and immunosuppressive therapy with horse anti-thymocyte globulin (h-ATG) and cyclosporine...” NCT03413306 ↗ 7 “Standard of Care immunosuppressive therapy (IST) includes HORSE ANTI-THYMOCYTE GLOBULIN (H-ATG) and Cyclosporine (CSA)” NCT07001254 ↗ “combination of hATG (horse anti-thymocyte globulin)” NCT01624805 ↗ “horse anti-thymocyte globulin (hATG)” NCT02462252 ↗ “horse antithymocyte globulin (h-ATG)” PMID 19181786 ↗ Jan 2009 NCT00944749 ↗ NCT02099747 ↗ NCT03025698 ↗
Known as	horse anti-thymocyte globulin (ATG)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05600426 ↗ 1 NCT02845596 ↗
Known as	horse anti-thymocyte globulin (hATG)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02462252 ↗
Known as	horse ATG	“Horse ATG (ATGAM) (hATG) is not considered an investigational medicinal product (IMP)” NCT03025698 ↗ 1 “standard horse ATG (h-ATG) plus cyclosporine (CsA)” PMID 24415649 ↗ Mar 2014
Known as	horse-antithymocyte globulin	“Aplastic anemia can be treated effectively with allogeneic bone marrow transplantation and immunosuppressive therapy with horse anti-thymocyte globulin (h-ATG) and cyclosporine...” NCT03413306 ↗ 8 “Standard of Care immunosuppressive therapy (IST) includes HORSE ANTI-THYMOCYTE GLOBULIN (H-ATG) and Cyclosporine (CSA)” NCT07001254 ↗ “Horses can also be used for this procedure to make horse-antithymocyte globulin (h-ATG).” NCT00944749 ↗ “Mérieux; horse antithymocyte globulin (ATG) + Cyclosporine A (CSA)” NCT00004208 ↗ “Horse Antithymocyte Globulin, Cyclosporine, Promacta, Eltrombopag” NCT01623167 ↗ “horse antithymocyte globulin (h-ATG)” PMID 19181786 ↗ Jan 2009 NCT04304820 ↗ NCT01019876 ↗ NCT00801931 ↗
Known as	ImtixSangstat	“The optimal dose of rabbit antithymocyte globulin (ATG, ImtixSangstat) minimizing infections without increasing graft-versus-host disease (GVHD) is unknown” PMID 31401973 ↗ Aug 2019
Known as	lymphocyte immune globulin	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04224558 ↗
Known as	r-ATG	“Protocol for Prospective Phase II Study of Rabbit Antithymocyte Globulin (r-ATG/Thymoglobulin) and Cyclosporine (CsA) as a First Line Immunosuppressive (IS) Therapy for Severe...” NCT01231841 ↗ 4 “Anti-Thymocyte Globulin, rabbit (r-ATG, Thymoglobulin®) is a polyclonal antibody against T-lymphocytes that is used for the prevention and treatment of acute allograft rejection.” NCT00331162 ↗ “Individual dose of Thymoglobulin (r-ATG) : Individual dose of ATG was Intravenous infused every day from day -5 to day -2” NCT04778618 ↗ “Anti-thymocyte Globulin (rATG), as Induction Therapy” NCT04311632 ↗ “low dose antithymocyte globulin rATG(2.5mg/kg/d)” NCT03395860 ↗
Known as	rabbit anti-human thymocyte immunoglobin	“The regimens for prophylaxis of GVHD based on 10mg/kg rabbit anti-human thymocyte immunoglobin (ATG, Thymoglobulin®, Genzyme Polyclonals S.A.S) effectively reduced the...” NCT04778618 ↗
Known as	rabbit Anti-thymocyte Globulin	“Therefore, rabbit-anti-thymocyte globulin has hematologic remitting activity in myelodysplastic syndrome and a T-cell activation profile has potential utility classifying those...” PMID 24488560 ↗ Jan 2014 2 “rabbit anti-thymocyte globulin (ATG) IV over at least 8-12 hours on days 1-4” NCT00017550 ↗ “another drug called (rabbit Anti-thymocyte Globulin [ATG])” NCT06315309 ↗
Known as	rabbit ATG	“conditioning regimen of alemtuzumab/Campath, anti-thymocyte globulin/rabbit ATG, Fludarabine and Melphalan and total body irradiation” NCT07284641 ↗
Known as	Rabbit thymoglobulin	“Rabbit thymoglobulin will be given intravenously at a dose of 2.5 mg/kg on days -5,-4, -3, and -2.” NCT00392782 ↗
Known as	Thymoglobin	“The regimens for prophylaxis of GVHD based on 10mg/kg rabbit anti-human thymocyte immunoglobin (ATG, Thymoglobin®, Genzyme Polyclonals S.A.S) effectively reduced the occurrence...” NCT05166967 ↗
Known as	Thymoglobulin	“The regimens for prophylaxis of GVHD based on 10mg/kg rabbit anti-human thymocyte immunoglobin (ATG, Thymoglobulin®, Genzyme Polyclonals S.A.S) effectively reduced the...” NCT04778618 ↗ 9 “Antithymocyte globulin (Thymoglobulin) 1.5 mg/kg/day (for HLA-matched sibling donor HCT) or 3.0 mg/kg/day (for other alternative donor HCT) i.v. daily on days -3 to -1 (for 3 days)” NCT06098326 ↗ “Anti-Thymocyte Globulin, rabbit (r-ATG, Thymoglobulin®) is a polyclonal antibody against T-lymphocytes that is used for the prevention and treatment of acute allograft rejection.” NCT00331162 ↗ “Antithymocyte globulin, or thymoglobulin, will be given IV daily for 4 days (days 7, 5, 3, and 1 before transplant).” NCT00133367 ↗ “ATG (Thymoglobulin®, Genzyme), at a dose of 1.5 mg/kg/d, will be given intravenously on days -11 through -7.” NCT00603954 ↗ “Rabbit thymoglobulin will be given intravenously at a dose of 2.5 mg/kg on days -5,-4, -3, and -2.” NCT00392782 ↗ “rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France).” NCT03412266 ↗ “rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France)” NCT03412409 ↗ “monitoring ATG (Thymoglobulin, Sanofi, Lyon, France) concentrations” PMID 41624481 ↗ Apr 2025 “Thymoglobulin® (Anti-thymocyte Globulin) - at first transplant” NCT00789308 ↗
Known as	Thymoglobulin [Anti-thymocyte Globulin	“Thymoglobulin® [Anti-thymocyte Globulin” NCT00795132 ↗
Known as	Thymoglobuline	“The purpose of this study is to determine if anti-thymocyte globulin (Thymoglobuline) administration in the kidney transplant recipient is able to reduce the amount of damage...” NCT01239563 ↗ 2 “Anti-thymocyte globulin (ATG-rabbit, Thymoglobuline®) 0.5 mg/kg body weight iv on day -5, 1.0 mg ATG-rabbit/kg will be given iv on day -4, and 1.5 mg ATG-rabbit /kg will be...” NCT03477500 ↗ “2.5 mg/Kg/day ATG (Thymoglobuline®) for 2 consecutive days (day -2 and -1)” NCT02876679 ↗
Known as	Timoglobulin SangStat	“Antithymocyte globulin (Timoglobulin SangStat)” NCT00488436 ↗
Known as	◦Drug: ATG	“◦Drug: ATG” NCT01983761 ↗
Action	Inhibit	“Treatments to abrogate T cell activity such as anti-thymocyte globulin alone and cyclosporine alone have demonstrated varying degrees of success in alleviating the cytopenia of MDS.” NCT00005937 ↗
Modality	Protein / enzyme biologic	“horse antithymocyte globulin (ATG)” NCT00004208 ↗
Route	Intravenous	“ATG will then be started, infused through a vein continuously for 4 days” NCT00001964 ↗